Published in Ann Oncol on March 09, 2007
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Rates of teratoma and viable cancer at post-chemotherapy retroperitoneal lymph node dissection after induction chemotherapy for good risk nonseminomatous germ cell tumors. J Urol (2014) 1.08
Update on management of seminoma. Indian J Urol (2010) 0.99
Canadian consensus guidelines for the management of testicular germ cell cancer. Can Urol Assoc J (2010) 0.92
Management of poor-prognosis testicular germ cell tumors. Indian J Urol (2010) 0.83
A review of second-line chemotherapy and prognostic models for disseminated germ cell tumors. Hematol Oncol Clin North Am (2011) 0.82
Management of the post chemotherapy subcentimeter residual mass: the case for observation. World J Urol (2009) 0.80
Development of a risk stratification system to guide treatment for female germ cell tumors. Gynecol Oncol (2015) 0.79
Good-risk-advanced germ cell tumors: historical perspective and current standards of care. World J Urol (2009) 0.77
Testosterone Level in Testicular Cancer Patients after Chemotherapy. West Indian Med J (2016) 0.75
SEOM clinical guidelines for the management of germ cell testicular cancer (2016). Clin Transl Oncol (2016) 0.75
Management of good-risk metastatic nonseminomatous germ cell tumors of the testis: current concepts and controversies. Indian J Urol (2010) 0.75
Nonseminomatous germ cell tumor with seizure disorder and mental retardation. Lung India (2009) 0.75
The Sound of Silence: A Proxy for Platinum Toxicity. J Clin Oncol (2016) 0.75
False elevation of human chorionic gonadotropin in a patient with testicular cancer. Nat Rev Urol (2010) 0.75
Optimal management of testicular cancer: from self-examination to treatment of advanced disease. Open Access J Urol (2010) 0.75
[Testicular yolk sac tumor: a rare entity in adults]. Pan Afr Med J (2014) 0.75
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer (1984) 3.94
A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol (2005) 3.53
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol (2011) 3.07
Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst (1995) 3.00
Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst (2009) 2.83
European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol (2004) 2.65
Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol (1996) 2.53
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol (2013) 2.41
Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol (1995) 2.29
Prognostic factors in localized primary synovial sarcoma: a multicenter study of 128 adult patients. J Clin Oncol (2001) 2.29
Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials. Ann Oncol (2000) 2.20
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med (1990) 2.15
High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. Eur J Cancer (1995) 2.10
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol (2008) 2.10
Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. J Clin Oncol (1998) 2.06
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol (2002) 2.03
Blood pressure values in 1116 French-Canadian children. Can Med Assoc J (1976) 2.03
Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol (2013) 1.97
Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Br J Cancer (1999) 1.96
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer (2011) 1.95
A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol (2009) 1.92
Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy. Ann Oncol (2010) 1.91
Reproducibility of a histopathologic grading system for adult soft tissue sarcoma. Cancer (1986) 1.88
A hopefully biased pilot survey of physicians' knowledge of the content of drug combinations. Can Med Assoc J (1973) 1.87
Delayed adjuvant tamoxifen: ten-year results of a collaborative randomized controlled trial in early breast cancer (TAM-02 trial) Ann Oncol (2000) 1.80
Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer (2001) 1.78
High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol (1996) 1.77
Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. Exp Hematol (2000) 1.77
Basal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized study. Br J Cancer (1997) 1.74
The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer (2000) 1.74
A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med (1992) 1.71
Chemotherapy for patients with locally advanced or metastatic Merkel cell carcinoma. Cancer (1999) 1.61
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol (1993) 1.60
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol (2010) 1.58
Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol (2009) 1.57
Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma. Ann Oncol (1992) 1.55
Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol (2007) 1.52
Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood (1993) 1.52
Analysis of complications in a prospective randomized trial comparing two brachytherapy low dose rates in cervical carcinoma. Int J Radiat Oncol Biol Phys (1994) 1.51
Tumor marker kinetics predict outcome in patients with relapsed disseminated non-seminomatous germ-cell tumors. Ann Oncol (2012) 1.49
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood (1998) 1.49
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol (1995) 1.49
Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol (2012) 1.44
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. Ann Oncol (2001) 1.44
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol (2008) 1.44
Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res (2001) 1.43
Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol (2014) 1.39
High failure rate of carboplatin-etoposide combination in good risk non-seminomatous germ cell tumours. Eur J Cancer (1993) 1.39
Primary treatment in stage II non-seminomatous germ cell tumours of the testis: a matter of scalpel or drug infusion? Eur J Cancer (1996) 1.38
Possible cohort effects in studies on oral contraceptive use and breast cancer. Br J Cancer (1985) 1.38
A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary. Gynecol Oncol (1994) 1.38
Nervous reactions after first dose of terfenadine in adults. Lancet (1989) 1.38
High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol (1998) 1.37
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol (1992) 1.37
Quality of life in long-term survivors of testicular cancer: a population-based case-control study. J Clin Oncol (2002) 1.33
Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res (2000) 1.30
A comparison of model choices for the Continual Reassessment Method in phase I cancer trials. Stat Med (2009) 1.30
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol (2011) 1.29
Extragonadal seminoma: an international multicenter analysis of prognostic factors and long term treatment outcome. Cancer (2001) 1.29
Coagulopathy in prostate cancer. Neth J Med (2003) 1.29
Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol (1996) 1.27
Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol (1996) 1.27
Insulin-Like Growth Factor (IGF) family and prostate cancer. Crit Rev Oncol Hematol (2006) 1.25
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. Ann Oncol (2012) 1.24
Five-year change in statistical designs of phase II trials published in leading cancer journals. Eur J Cancer (2004) 1.24
Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients. Cancer (1996) 1.23
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol (2007) 1.22
Hematologic disorders associated with primary mediastinal nonseminomatous germ cell tumors. J Natl Cancer Inst (2000) 1.21
Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer (2001) 1.21
Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol (1994) 1.21
Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer. Dis Markers (2000) 1.20
Bilateral germ-cell tumours: 22-year experience at the Institut Gustave Roussy. Br J Cancer (2004) 1.20
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group. J Clin Oncol (2001) 1.20